Ten Medicare Advantage Insurers Now Suing Over 2027 Star Ratings as Seniors Weigh Plans Before December 7 Deadline

Ten Medicare Advantage insurers, including CVS Health, Centene, and Elevance Health, have sued the federal government over their 2027 star ratings. They argue CMS used unauthorized quality measures, with CVS estimating a $2B impact in 2028. Star ratings influence bonus payments and plan rebates, affecting benefits. Open enrollment ends Dec. 7, 2026.

Original reporting
Published Nov 13, 2026, 1:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 6:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ten Medicare Advantage Insurers Now Suing Over 2027 Star Ratings as Seniors Weigh Plans Before December 7 Deadline — source image
Decision brief

The 30-second read

$CVSBearishLow
01

Why it matters

The lawsuits introduce regulatory risk and uncertainty around future quality bonus payments, which could affect insurer valuations ahead of the Dec. 7 enrollment deadline.

02

Market read

The litigation could pressure U.S. health‑insurance stocks as investors assess potential bonus payment reductions before the enrollment deadline.

03

What to watch

The outcome of the Clover Health precedent and possible CMS rule changes could mitigate the lawsuits' impact.

Relevance 6/10Novelty 7/10Timing: before Dec. 7 enrollment deadline

Background

A growing coalition of Medicare Advantage insurers is suing CMS over the methodology of 2027 star ratings, citing potential billions in lost bonus payments.

Company-level read

Ticker impact

$CVSBearishHigh confidence
Context

CVS Health claims lower 2027 star ratings could cut its 2028 bonus payments by about $2 billion, prompting its lawsuit.

Expected impact

likely pressure as the market prices in the $2 billion bonus hit risk

Evidence & confidence

The lawsuit directly ties a large financial hit to the star rating dispute, creating material uncertainty.

$CNCBearishMedium confidence
Context

Centene says it could lose $448 million from the star‑rating dispute and faces low‑performance warnings.

Expected impact

moderate pressure from the disclosed $448 million potential loss

Evidence & confidence

The disclosed loss figure is sizable but smaller than CVS's, suggesting a less severe impact.

$ELVBearishLow confidence
Context

Elevance Health is listed among the insurers suing over the 2027 star ratings, indicating exposure to the same regulatory risk.

Expected impact

possible slight pressure due to litigation exposure

Evidence & confidence

No specific loss amount disclosed for Elevance, so impact is less certain.

Market effects

Medicare Advantage insurers may see heightened regulatory scrutiny and potential adjustments to quality bonus structures.

U.S. health‑insurance sector could experience modest volatility ahead of open enrollment.

Limited to U.S. healthcare markets; no direct global spillover.

Counterpoint

If courts limit CMS's authority, insurers could retain higher bonus payments, potentially boosting stocks.

Key entities

  • CVS Health

    U.S. pharmacy and health‑services company filing lawsuit over star ratings.

  • Centene

    Managed‑care insurer estimating $448 million loss from rating dispute.

  • Elevance Health

    Health‑insurance firm joining the litigation group.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$CVSHigh

CVS Health Falls as Medicare Advantage Scrutiny Adds to Breakup Overhang

CVS Health (CVS) fell 3.5% due to Medicare Advantage regulatory risks and uncertainty around its planned business separation. CMS proposed tighter oversight, raising concerns about Aetna's compliance costs. CVS announced a split into two public companies, with risks tied to timing, approvals, and costs. Insider and hedge fund activity, along with analyst ratings, were also noted.

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.